256 related articles for article (PubMed ID: 31883941)
1. Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy.
Kijima T; Tanaka H; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
Clin Genitourin Cancer; 2020 Aug; 18(4):268-273.e2. PubMed ID: 31883941
[TBL] [Abstract][Full Text] [Related]
2. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer.
Tanaka H; Fukushima H; Kijima T; Nakamura Y; Yajima S; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
Int J Urol; 2020 Mar; 27(3):236-243. PubMed ID: 31957164
[TBL] [Abstract][Full Text] [Related]
5. High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.
Tanabe K; Yoshida S; Koga F; Inoue M; Kobayashi S; Ishioka J; Tamura T; Sugawara E; Saito K; Akashi T; Fujii Y; Kihara K
Clin Genitourin Cancer; 2015 Aug; 13(4):e243-e251. PubMed ID: 25936588
[TBL] [Abstract][Full Text] [Related]
6. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study.
Fujiwara M; Yokoyama M; Toide M; Fujiwara R; Tanaka H; Oguchi T; Komai Y; Yoshida S; Matsuoka Y; Numao N; Yamamoto S; Fukui I; Yonese J; Fujii Y
Jpn J Clin Oncol; 2023 Mar; 53(3):263-269. PubMed ID: 36524369
[TBL] [Abstract][Full Text] [Related]
7. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
9. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
10. Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach.
Inoue M; Koga F; Yoshida S; Tamura T; Fujii Y; Ito E; Kihara K
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):303-11. PubMed ID: 25304790
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
13. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.
Gakis G; Efstathiou J; Lerner SP; Cookson MS; Keegan KA; Guru KA; Shipley WU; Heidenreich A; Schoenberg MP; Sagaloswky AI; Soloway MS; Stenzl A;
Eur Urol; 2013 Jan; 63(1):45-57. PubMed ID: 22917985
[TBL] [Abstract][Full Text] [Related]
14. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
15. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Long-term results [corrected].
Aluwini S; van Rooij PH; Kirkels WJ; Boormans JL; Kolkman-Deurloo IK; Wijnmaalen A
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):611-7. PubMed ID: 24411629
[TBL] [Abstract][Full Text] [Related]
16. Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?
Cha EK; Donahue TF; Bochner BH
Urol Clin North Am; 2015 May; 42(2):189-99, viii. PubMed ID: 25882561
[TBL] [Abstract][Full Text] [Related]
17. The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy.
Marks P; Gild P; Soave A; Janisch F; Minner S; Engel O; Vetterlein MW; Shariat SF; Sauter G; Dahlem R; Fisch M; Rink M
Surg Oncol; 2019 Mar; 28():208-213. PubMed ID: 30851902
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants.
Naspro R; La Croce G; Finati M; Roscigno M; Pellucchi F; Sodano M; Manica M; Gianatti A; Da Pozzo LF
Urol Oncol; 2022 Feb; 40(2):61.e9-61.e19. PubMed ID: 34334293
[TBL] [Abstract][Full Text] [Related]
19. Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study.
Riesterer O; Ademaj A; Puric E; Eberle B; Beck M; Gomez S; Marder D; Oberacker E; Rogers S; Hälg RA; Kern T; Schwenne S; Stein J; Stutz E; Timm O; Zschaeck S; Weyland MS; Veltsista PD; Wyler S; Wust P; Scheidegger S; Bodis S; Ghadjar P
Int J Hyperthermia; 2022; 39(1):1078-1087. PubMed ID: 35993234
[TBL] [Abstract][Full Text] [Related]
20. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
